Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Signals Interest In Requiring Unique Biosimilar Names

This article was originally published in The Pink Sheet Daily

Executive Summary

OND Director Jenkins expresses concern at a public hearing that the agency could miss or confuse some spontaneous adverse events if biosimilars are not distinguished from their reference product.

You may also be interested in...



Supply Chain Security Issues To Emerge During Subcommittee Hearing On PDUFA

FDA's Biosimilar Strategy Will Rely On "Fingerprint" Technology To Limit Trials

European experiences with "totality of the evidence" method also seem to be shaping policy, according to FDA article in NEJM.

FDA's Biosimilar Strategy Will Rely On "Fingerprint" Technology To Limit Trials

European experiences with "totality of the evidence" method also seem to be shaping policy, according to FDA article in NEJM.

Related Content

Topics

UsernamePublicRestriction

Register

ID1132028

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel